메뉴 건너뛰기




Volumn 10, Issue 5, 2010, Pages 581-590

Novel biomarkers of metastatic cancer

Author keywords

biomarkers; BRAF; circulating tumor cells; HER2; KRAS; metastatic cancer; microRNA

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CD20 ANTIGEN; CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEFITINIB; HORMONE RECEPTOR; IMATINIB; K RAS PROTEIN; MICRORNA; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; RITUXIMAB; RNA; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; ERBB2 PROTEIN, HUMAN;

EID: 77954726604     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.35     Document Type: Review
Times cited : (15)

References (98)
  • 1
    • 0000078117 scopus 로고    scopus 로고
    • Molecular biology of cancer: Invasion and metastases
    • Devita VT, Hellman, S, Rosenberg SA (Eds). Lippincott- Raven, PA, USA
    • Fidler IJ. Molecular biology of cancer: invasion and metastases. In: Cancer Principles and Practice of Oncology. Devita VT, Hellman, S, Rosenberg SA (Eds). Lippincott- Raven, PA, USA, 135-152 (1997).
    • (1997) Cancer Principles and Practice of Oncology , pp. 135-152
    • Fidler, I.J.1
  • 2
    • 0026008680 scopus 로고
    • Metastatic breast cancer: Length and quality of life
    • Norton L. Metastatic breast cancer: length and quality of life. N. Engl. J. Med. 325, 1370-1371 (1991).
    • (1991) N. Engl. J. Med. , vol.325 , pp. 1370-1371
    • Norton, L.1
  • 3
    • 41649102043 scopus 로고    scopus 로고
    • The cancer biomarker problem
    • Sawyers CL. The cancer biomarker problem. Nature 452(7187), 548-552 (2008).
    • (2008) Nature , vol.452 , Issue.7187 , pp. 548-552
    • Sawyers, C.L.1
  • 4
    • 28544446695 scopus 로고    scopus 로고
    • Biomarkers in cancer staging, prognosis and treatment selection
    • Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5(11), 845-856 (2005).
    • (2005) Nat. Rev. Cancer , vol.5 , Issue.11 , pp. 845-856
    • Ludwig, J.A.1    Weinstein, J.N.2
  • 5
    • 0036674501 scopus 로고    scopus 로고
    • Dissemination and growth of cancer cells in metastatic sites
    • Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572 (2002).
    • (2002) Nat. Rev. Cancer , vol.2 , pp. 563-572
    • Chambers, A.F.1    Groom, A.C.2    MacDonald, I.C.3
  • 6
    • 0036675220 scopus 로고    scopus 로고
    • Metastases to bone: Causes, consequences and therapeutic opportunities
    • Mundy GR. Metastases to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593 (2002).
    • (2002) Nat. Rev. Cancer , vol.2 , pp. 584-593
    • Mundy, G.R.1
  • 7
    • 0018864610 scopus 로고
    • The pathogenesis of cancer metastasis
    • Poste G and Fidler IJ. The pathogenesis of cancer metastasis. Nature 283, 139-146 (1980).
    • (1980) Nature , vol.283 , pp. 139-146
    • Poste, G.1    Fidler, I.J.2
  • 8
    • 0037226593 scopus 로고    scopus 로고
    • A molecular signature of metastasis in primary solid tumors
    • Ramaswamy S, Ross KN, Lander ES and Golub TR. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33, 49-54 (2003).
    • (2003) Nat. Genet. , vol.33 , pp. 49-54
    • Ramaswamy, S.1    Ross, K.N.2    Lander, E.S.3    Golub, T.R.4
  • 9
    • 0034680102 scopus 로고    scopus 로고
    • Molecular portraits of human breast tumors
    • Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature 406, 747-752 (2000).
    • (2000) Nature , vol.406 , pp. 747-752
    • Perou, C.M.1    Sorlie, T.2    Eisen, M.B.3
  • 10
    • 0035845511 scopus 로고    scopus 로고
    • Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
    • Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
    • (2001) Proc. Natl Acad. Sci. USA , vol.98 , pp. 10869-10874
    • Sorlie, T.1    Perou, C.M.2    Tibshirani, R.3
  • 11
    • 66549111590 scopus 로고    scopus 로고
    • Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up
    • Cardoso F, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), 15-18 (2009).
    • (2009) Ann. Oncol. , vol.20 , Issue.SUPPL. 4 , pp. 15-18
    • Cardoso, F.1    Castiglione, M.2
  • 12
    • 63549116437 scopus 로고    scopus 로고
    • Survival among women with triple receptor-negative breast cancer and brain metastases
    • Dawood S, Broglio K, Esteva FJ et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann. Oncol. 20(4), 621-627 (2009).
    • (2009) Ann. Oncol. , vol.20 , Issue.4 , pp. 621-627
    • Dawood, S.1    Broglio, K.2    Esteva, F.J.3
  • 13
    • 70449698237 scopus 로고    scopus 로고
    • Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases
    • Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J. Clin. Oncol. 27(31), 5278-5286 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.31 , pp. 5278-5286
    • Leyland-Jones, B.1
  • 14
    • 23144461051 scopus 로고    scopus 로고
    • Genes that mediate breast cancer metastasis to lung
    • Minn AJ, Gupta GP, Siegel PM et al. Genes that mediate breast cancer metastasis to lung. Nature 436(7050), 518-524 (2005).
    • (2005) Nature , vol.436 , Issue.7050 , pp. 518-524
    • Minn, A.J.1    Gupta, G.P.2    Siegel, P.M.3
  • 15
    • 58149340543 scopus 로고    scopus 로고
    • Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer
    • Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin. Cancer Res. 4(24), 8019-8026 (2008).
    • (2008) Clin. Cancer Res. , vol.4 , Issue.24 , pp. 8019-8026
    • Dowsett, M.1    Dunbier, A.K.2
  • 16
    • 19944422061 scopus 로고    scopus 로고
    • A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    • Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
    • (2004) N. Engl. J. Med. , vol.351 , Issue.27 , pp. 2817-2826
    • Paik, S.1    Shak, S.2    Tang, G.3
  • 17
    • 0037137519 scopus 로고    scopus 로고
    • A gene-expression signature as a predictor of survival in breast cancer
    • van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002).
    • (2002) N. Engl. J. Med. , vol.347 , Issue.25 , pp. 1999-2009
    • Van De Vijver, M.J.1    He, Y.D.2    Van'T Veer, L.J.3
  • 19
    • 58149232649 scopus 로고    scopus 로고
    • Unraveling the biologic and clinical complexities of HER2
    • Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic and clinical complexities of HER2. Clin. Breast Cancer 8(5), 392-401 (2008).
    • (2008) Clin. Breast Cancer , vol.8 , Issue.5 , pp. 392-401
    • Park, J.W.1    Neve, R.M.2    Szollosi, J.3    Benz, C.C.4
  • 20
    • 73349085919 scopus 로고    scopus 로고
    • Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer
    • Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 27(34), 5838-5847 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.34 , pp. 5838-5847
    • Spector, N.L.1    Blackwell, K.L.2
  • 21
    • 50849123421 scopus 로고    scopus 로고
    • HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target
    • Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19(9), 1523-1529 (2008).
    • (2008) Ann. Oncol. , vol.19 , Issue.9 , pp. 1523-1529
    • Gravalos, C.1    Jimeno, A.2
  • 22
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
    • (2001) N. Engl. J. Med. , vol.344 , Issue.11 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 23
    • 73949090721 scopus 로고    scopus 로고
    • Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review
    • Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol. 28(1), 92-98 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.1 , pp. 92-98
    • Dawood, S.1    Broglio, K.2    Buzdar, A.U.3    Hortobagyi, G.N.4    Giordano, S.H.5
  • 24
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    • Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
    • (2005) N. Engl. J. Med. , vol.353 , Issue.16 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3
  • 25
    • 26844503270 scopus 로고    scopus 로고
    • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    • Piccart-Gebhart MJ, Procter M, Leyland- Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
    • (2005) N. Engl. J. Med. , vol.353 , Issue.16 , pp. 1659-1672
    • Piccart-Gebhart, M.J.1    Procter, M.2    Leyland- Jones, B.3
  • 26
    • 70350204423 scopus 로고    scopus 로고
    • Efficacy results from the ToGA trial: A Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
    • Abstract LBA4509
    • Van Cutsem E, KangY , Chung H et al. Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol. 27(Suppl.), 18s (2009) (Abstract LBA4509).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.SUPPL.
    • Van Cutsem, E.1    Kangy Chung, H.2
  • 27
    • 11244258222 scopus 로고    scopus 로고
    • Epidermal growth factor receptor inhibition strategies in oncology
    • Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer 11 (4), 689-708 (2004).
    • (2004) Endocr. Relat. Cancer , vol.11 , Issue.4 , pp. 689-708
    • Harari, P.M.1
  • 29
    • 0030980781 scopus 로고    scopus 로고
    • Over expression of the epidermal growth factor receptor and its ligand transforming growth a is frequent in resectable non-small cell lung cancer but does not predict tumor progression
    • Rusch VD, Klimstra E, Venkatraman P et al. Over expression of the epidermal growth factor receptor and its ligand transforming growth a is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 3, 515-522 (1997).
    • (1997) Clin. Cancer Res. , vol.3 , pp. 515-522
    • Rusch, V.D.1    Klimstra, E.2    Venkatraman, P.3
  • 30
    • 0142119289 scopus 로고    scopus 로고
    • Epidermal growth factor receptor in non-small cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis
    • Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21, 3798-3807 (2003).
    • (2003) J. Clin. Oncol. , vol.21 , pp. 3798-3807
    • Hirsch, F.R.1    Varella-Garcia, M.2    Bunn Jr., P.A.3
  • 31
    • 3042663513 scopus 로고    scopus 로고
    • Cetuximab in advanced non-small cell lung cancer
    • Govindan R. Cetuximab in advanced non-small cell lung cancer. Clin. Cancer Res. 10, 4241s-4244s (2004).
    • (2004) Clin. Cancer Res. , vol.10
    • Govindan, R.1
  • 32
    • 65349116059 scopus 로고    scopus 로고
    • Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised Phase III trial
    • Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. Lancet 373(9674), 1525-1531 (2009).
    • (2009) Lancet , vol.373 , Issue.9674 , pp. 1525-1531
    • Pirker, R.1    Pereira, J.R.2    Szczesna, A.3
  • 33
    • 39849111354 scopus 로고    scopus 로고
    • A randomized multicenter Phase III study of cetuximab (Erbitux) in combination with taxane/carboplatin alone as first-line treatment for patients with advanced/ metastatic non-small lung cancer (NSCLC)
    • Lynch TJ, Patel T, Dreisbach L et al. A randomized multicenter Phase III study of cetuximab (Erbitux) in combination with taxane/carboplatin alone as first-line treatment for patients with advanced/ metastatic non-small lung cancer (NSCLC). J. Thorac. Oncol. 2, S340-S341 (2007).
    • (2007) J. Thorac. Oncol. , vol.2
    • Lynch, T.J.1    Patel, T.2    Dreisbach, L.3
  • 34
    • 74949133978 scopus 로고    scopus 로고
    • American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
    • Azzoli CG, Baker S Jr, Temin S et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 27(36), 6251-6266 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.36 , pp. 6251-6266
    • Azzoli, C.G.1    Baker Jr., S.2    Temin, S.3
  • 35
    • 4444344330 scopus 로고    scopus 로고
    • EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    • Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004).
    • (2004) Proc. Natl Acad. Sci. USA , vol.101 , pp. 13306-13311
    • Pao, W.1    Miller, V.2    Zakowski, M.3
  • 36
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib
    • Lynch TJ, Bell DW Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
    • (2004) N. Engl. J. Med. , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 37
    • 70349376330 scopus 로고    scopus 로고
    • Molecular predictive and prognostic markers in non-small-cell lung cancer
    • Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol. 10(10), 1001-1010 (2009).
    • (2009) Lancet Oncol. , vol.10 , Issue.10 , pp. 1001-1010
    • Coate, L.E.1    John, T.2    Tsao, M.S.3    Shepherd, F.A.4
  • 38
    • 24944440830 scopus 로고    scopus 로고
    • TRIBUTE: A Phase III trial of erlotinib hydrochloride (OSI) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    • Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5892-5899 (2005).
    • (2005) J. Clin. Oncol. , vol.23 , pp. 5892-5899
    • Herbst, R.S.1    Prager, D.2    Hermann, R.3
  • 39
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
    • (2009) N. Engl. J. Med. , vol.361 , Issue.10 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 40
    • 70349388721 scopus 로고    scopus 로고
    • Understanding prognostic gene expression signatures in lung cancer
    • Zhu CQ, Pintilie M, John T et al. Understanding prognostic gene expression signatures in lung cancer. Clin. Lung Cancer 10(5), 331-340 (2009).
    • (2009) Clin. Lung Cancer , vol.10 , Issue.5 , pp. 331-340
    • Zhu, C.Q.1    Pintilie, M.2    John, T.3
  • 41
    • 61549108338 scopus 로고    scopus 로고
    • EGFR T790M mutation: A double role in lung cancer cell survival?
    • Suda K, Onozato R, Yatabe Y, Mitsudomi T. EGFR T790M mutation: a double role in lung cancer cell survival? J. Thorac. Oncol. 4(1), 1-4 (2009).
    • (2009) J. Thorac. Oncol. , vol.4 , Issue.1 , pp. 1-4
    • Suda, K.1    Onozato, R.2    Yatabe, Y.3    Mitsudomi, T.4
  • 42
    • 2142641698 scopus 로고    scopus 로고
    • Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    • Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22(7), 1201-1208 (2004).
    • (2004) J. Clin. Oncol. , vol.22 , Issue.7 , pp. 1201-1208
    • Saltz, L.B.1    Meropol, N.J.2    Loehrer Sr., P.J.3    Needle, M.N.4    Kopit, J.5    Mayer, R.J.6
  • 43
    • 20144381957 scopus 로고    scopus 로고
    • Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    • Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23(9), 1803-1810 (2005).
    • (2005) J. Clin. Oncol. , vol.23 , Issue.9 , pp. 1803-1810
    • Chung, K.Y.1    Shia, J.2    Kemeny, N.E.3
  • 44
    • 17844362179 scopus 로고    scopus 로고
    • Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study
    • Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6(5), 279-286 (2005).
    • (2005) Lancet Oncol. , vol.6 , Issue.5 , pp. 279-286
    • Moroni, M.1    Veronese, S.2    Benvenuti, S.3
  • 46
    • 35148842402 scopus 로고    scopus 로고
    • Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor (EGFr) levels: An updated analysis
    • Abstract 4081
    • Mitchell EP , Hecht JR, Baranda J et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor (EGFr) levels: an updated analysis. J. Clin. Oncol. 25(18 Suppl.) (2007) (Abstract 4081).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18 SUPPL.
    • Mitchell, E.P.1    Hecht, J.R.2    Baranda, J.3
  • 47
    • 70349939382 scopus 로고    scopus 로고
    • Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer
    • Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst. 101(19), 1308-1324 (2009).
    • (2009) J. Natl Cancer Inst. , vol.101 , Issue.19 , pp. 1308-1324
    • Siena, S.1    Sartore-Bianchi, A.2    Di Nicolantonio, F.3    Balfour, J.4    Bardelli, A.5
  • 48
    • 0024376173 scopus 로고
    • Ras oncogenes in human cancer: A review
    • Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 49(17), 4682-4689 (1989).
    • (1989) Cancer Res. , vol.49 , Issue.17 , pp. 4682-4689
    • Bos, J.L.1
  • 49
    • 33748063941 scopus 로고    scopus 로고
    • Roles of the RAF/MEK/ERK and PI3k/PTEN/AKT pathways in malignant transformation and drug resistance
    • McCubrey JA, Steelman LS, Abrams SL et al. Roles of the RAF/MEK/ERK and PI3k/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 46(1), 249-279 (2006).
    • (2006) Adv. Enzyme Regul. , vol.46 , Issue.1 , pp. 249-279
    • McCubrey, J.A.1    Steelman, L.S.2    Abrams, S.L.3
  • 50
    • 0025312728 scopus 로고
    • A genetic model for colorectal tumorigenesis
    • Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61(5), 759-767 (1990).
    • (1990) Cell , vol.61 , Issue.5 , pp. 759-767
    • Fearon, E.R.1    Vogelstein, B.2
  • 51
    • 42149083899 scopus 로고    scopus 로고
    • Mutations in the RAS-MAPK PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
    • Barault L, Veyrie N, Jooste V et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int. J. Cancer 122(10), 2255-2259 (2008).
    • (2008) Int. J. Cancer , vol.122 , Issue.10 , pp. 2255-2259
    • Barault, L.1    Veyrie, N.2    Jooste, V.3
  • 52
    • 0032855959 scopus 로고    scopus 로고
    • K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: A combined analysis of 881 cases
    • Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 20(8), 1507-1510 (1999).
    • (1999) Carcinogenesis , vol.20 , Issue.8 , pp. 1507-1510
    • Huncharek, M.1    Muscat, J.2    Geschwind, J.F.3
  • 53
    • 42649145667 scopus 로고    scopus 로고
    • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
    • (2008) J. Clin. Oncol. , vol.26 , pp. 1626-1634
    • Amado, R.G.1    Wolf, M.2    Peeters, M.3
  • 54
    • 51649120733 scopus 로고    scopus 로고
    • KRAS status and efficacy of first-line treatment of patients with metastatic colorectal (metastatic CRC) with FOLFOX with or without cetuximab: The OPUS experience
    • Abstract 4000
    • Bokemeyer C, Bondarenko I, Hartmann JT et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal (metastatic CRC) with FOLFOX with or without cetuximab: the OPUS experience. J. Clin. Oncol. 26(Suppl.), 178s (2008) (Abstract 4000).
    • (2008) J. Clin. Oncol. , vol.26 , Issue.SUPPL.
    • Bokemeyer, C.1    Bondarenko, I.2    Hartmann, J.T.3
  • 55
    • 54949085398 scopus 로고    scopus 로고
    • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    • Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008)
    • (2008) N. Engl. J. Med. , vol.359 , pp. 1757-1765
    • Karapetis, C.S.1    Khambata-Ford, S.2    Jonker, D.J.3
  • 56
    • 49149109102 scopus 로고    scopus 로고
    • Randomized Phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)
    • Abstract LBA4011
    • Punt CJ, Tol J, Rodenburg CJ et al. Randomized Phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J. Clin. Oncol. 26(Suppl.), 180s (2008) (Abstract LBA4011).
    • (2008) J. Clin. Oncol. , vol.26 , Issue.SUPPL.
    • Punt, C.J.1    Tol, J.2    Rodenburg, C.J.3
  • 57
    • 51649120733 scopus 로고    scopus 로고
    • KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (metastatic CRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
    • Abstract 2
    • Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (metastatic CRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J. Clin. Oncol. 26(Suppl.), 5s (2008) (Abstract 2).
    • (2008) J. Clin. Oncol. , vol.26 , Issue.SUPPL.
    • Van Cutsem, E.1    Lang, I.2    D'Haens, G.3
  • 58
    • 65349189958 scopus 로고    scopus 로고
    • American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
    • Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27(12), 2091-2096 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.12 , pp. 2091-2096
    • Allegra, C.J.1    Jessup, J.M.2    Somerfield, M.R.3
  • 59
    • 57449095367 scopus 로고    scopus 로고
    • Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
    • Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26(35), 5705-5712 (2008).
    • (2008) J. Clin. Oncol. , vol.26 , Issue.35 , pp. 5705-5712
    • Di Nicolantonio, F.1    Martini, M.2    Molinari, F.3
  • 60
    • 67649652208 scopus 로고    scopus 로고
    • BRAF mutation in metastatic colorectal cancer
    • Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361(1), 98-99 (2009).
    • (2009) N. Engl. J. Med. , vol.361 , Issue.1 , pp. 98-99
    • Tol, J.1    Nagtegaal, I.D.2    Punt, C.J.3
  • 61
    • 35348908314 scopus 로고    scopus 로고
    • PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
    • Frattini M, Saletti P, Romagnani E et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 97(8), 1139-1145 (2007).
    • (2007) Br. J. Cancer , vol.97 , Issue.8 , pp. 1139-1145
    • Frattini, M.1    Saletti, P.2    Romagnani, E.3
  • 62
    • 62449302407 scopus 로고    scopus 로고
    • PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
    • Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69(5), 1851-1857 (2009).
    • (2009) Cancer Res. , vol.69 , Issue.5 , pp. 1851-1857
    • Sartore-Bianchi, A.1    Martini, M.2    Molinari, F.3
  • 63
    • 33751377398 scopus 로고    scopus 로고
    • The clinical significance of circulating tumor cells in the peripheral blood
    • Elshimali YI, Grody WW. The clinical significance of circulating tumor cells in the peripheral blood. Diagn. Mol. Pathol. 15(4), 187-194 (2006).
    • (2006) Diagn. Mol. Pathol. , vol.15 , Issue.4 , pp. 187-194
    • Elshimali, Y.I.1    Grody, W.W.2
  • 64
    • 0036595629 scopus 로고    scopus 로고
    • Epithelial-mesenchymal transitions in tumour progression
    • Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2(6), 442-454 (2002).
    • (2002) Nat. Rev. Cancer , vol.2 , Issue.6 , pp. 442-454
    • Thiery, J.P.1
  • 65
    • 34848826864 scopus 로고    scopus 로고
    • Epithelial - Mesenchymal and mesenchymal - Epithelial transitions in carcinoma progression
    • Hugo H, Ackland ML, Blick T et al. Epithelial - mesenchymal and mesenchymal - epithelial transitions in carcinoma progression. J. Cell Physiol. 213(2), 374-383 (2007).
    • (2007) J. Cell Physiol. , vol.213 , Issue.2 , pp. 374-383
    • Hugo, H.1    Ackland, M.L.2    Blick, T.3
  • 66
    • 75449084154 scopus 로고    scopus 로고
    • Circulating tumor cells: Evolving evidence and future challenges
    • Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating tumor cells: evolving evidence and future challenges. Oncologist 14(11), 1070-1082 (2009).
    • (2009) Oncologist , vol.14 , Issue.11 , pp. 1070-1082
    • Dotan, E.1    Cohen, S.J.2    Alpaugh, K.R.3    Meropol, N.J.4
  • 67
    • 6044259206 scopus 로고    scopus 로고
    • Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
    • Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10, 6897-6904 (2004).
    • (2004) Clin. Cancer Res. , vol.10 , pp. 6897-6904
    • Allard, W.J.1    Matera, J.2    Miller, M.C.3
  • 68
    • 4143094988 scopus 로고    scopus 로고
    • Circulating tumor cells predict progression free survival and overall survival in metastatic breast cancer
    • Cristofanilli M, Budd GT, Ellis M et al. Circulating tumor cells predict progression free survival and overall survival in metastatic breast cancer. N. Engl. J. Med. 351, 781-791 (2004).
    • (2004) N. Engl. J. Med. , vol.351 , pp. 781-791
    • Cristofanilli, M.1    Budd, G.T.2    Ellis, M.3
  • 69
    • 33947286218 scopus 로고    scopus 로고
    • Circulating tumor cells in metastatic breast cancer: Biologic staging beyond tumor burden
    • Cristofanilli M, Broglio KR, Guarneri V et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin. Breast Cancer 6, 471-479 (2007).
    • (2007) Clin. Breast Cancer , vol.6 , pp. 471-479
    • Cristofanilli, M.1    Broglio, K.R.2    Guarneri, V.3
  • 70
    • 33846814619 scopus 로고    scopus 로고
    • Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival
    • Hayes DF, Cristofanilli M, Budd GT et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 12(14), 4218-4224 (2006).
    • (2006) Clin. Cancer Res. , vol.12 , Issue.14 , pp. 4218-4224
    • Hayes, D.F.1    Cristofanilli, M.2    Budd, G.T.3
  • 72
    • 55549115023 scopus 로고    scopus 로고
    • Circulating tumor cells in metastatic breast cancer: From prognostic stratification to modification of the staging system?
    • Dawood S, Broglio K, Valero V et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer 113(9), 2422-2430 (2008).
    • (2008) Cancer , vol.113 , Issue.9 , pp. 2422-2430
    • Dawood, S.1    Broglio, K.2    Valero, V.3
  • 73
    • 70449561613 scopus 로고    scopus 로고
    • Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients
    • Pestrin M, Bessi S, Galardi F et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res. Treat. 118(3), 523-530 (2009).
    • (2009) Breast Cancer Res. Treat. , vol.118 , Issue.3 , pp. 523-530
    • Pestrin, M.1    Bessi, S.2    Galardi, F.3
  • 74
    • 40449098857 scopus 로고    scopus 로고
    • Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
    • Fehm T, Becker S, Duerr-Stoerzer S et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 9(5), R74 (2007).
    • (2007) Breast Cancer Res. , vol.9 , Issue.5
    • Fehm, T.1    Becker, S.2    Duerr-Stoerzer, S.3
  • 75
    • 3042552362 scopus 로고    scopus 로고
    • HER-2 gene amplification can be acquired as breast cancer progresses
    • Meng S, Tripathy D, Shete S et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl Acad. Sci. USA 101(25), 9393-9398 (2004).
    • (2004) Proc. Natl Acad. Sci. USA , vol.101 , Issue.25 , pp. 9393-9398
    • Meng, S.1    Tripathy, D.2    Shete, S.3
  • 76
    • 17144426134 scopus 로고    scopus 로고
    • Circulating tumor cells predict survival in patients with metastatic prostate cancer
    • Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65(4), 713-718 (2005).
    • (2005) Urology , vol.65 , Issue.4 , pp. 713-718
    • Moreno, J.G.1    Miller, M.C.2    Gross, S.3    Allard, W.J.4    Gomella, L.G.5    Terstappen, L.W.6
  • 78
    • 34247502671 scopus 로고    scopus 로고
    • Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
    • Shaffer DR, Leversha MA, Danila DC et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin. Cancer Res. 13(7), 2023-2029 (2007).
    • (2007) Clin. Cancer Res. , vol.13 , Issue.7 , pp. 2023-2029
    • Shaffer, D.R.1    Leversha, M.A.2    Danila, D.C.3
  • 79
    • 33749031540 scopus 로고    scopus 로고
    • Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer
    • Cohen SJ, Alpaugh RK, Gross S et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 6(2), 125-132 (2006).
    • (2006) Clin. Colorectal Cancer , vol.6 , Issue.2 , pp. 125-132
    • Cohen, S.J.1    Alpaugh, R.K.2    Gross, S.3
  • 80
    • 49249130844 scopus 로고    scopus 로고
    • Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
    • Cohen SJ, Punt CJ, Iannotti N. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(19), 3213-3221 (2008).
    • (2008) J. Clin. Oncol. , vol.26 , Issue.19 , pp. 3213-3221
    • Cohen, S.J.1    Punt, C.J.2    Iannotti, N.3
  • 81
    • 77952419985 scopus 로고    scopus 로고
    • Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents
    • Tol J, Koopman M, Miller MC et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann. Oncol. 21(5), 1006-1012 (2010).
    • (2010) Ann. Oncol. , vol.21 , Issue.5 , pp. 1006-1012
    • Tol, J.1    Koopman, M.2    Miller, M.C.3
  • 82
    • 0141843656 scopus 로고    scopus 로고
    • The nuclear RNase III Drosha initiates microRNA processing
    • Lee Y, Ahn C, Han J et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956), 415-419 (2003).
    • (2003) Nature , vol.425 , Issue.6956 , pp. 415-419
    • Lee, Y.1    Ahn, C.2    Han, J.3
  • 83
    • 0035800521 scopus 로고    scopus 로고
    • A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA
    • Hutvágner G, McLachlan J, Pasquinelli AE, Bálint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293(5531), 834-838 (2001).
    • (2001) Science , vol.293 , Issue.5531 , pp. 834-838
    • Hutvágner, G.1    McLachlan, J.2    Pasquinelli, A.E.3    Bálint, E.4    Tuschl, T.5    Zamore, P.D.6
  • 84
    • 77949261485 scopus 로고    scopus 로고
    • MicroRNAs in cancer - From research to therapy
    • Cho WC. MicroRNAs in cancer - from research to therapy. Biochim. Biophys. Acta 1805(2), 209-217 (2010).
    • (2010) Biochim. Biophys. Acta , vol.1805 , Issue.2 , pp. 209-217
    • Cho, W.C.1
  • 85
    • 77954386364 scopus 로고    scopus 로고
    • MicroRNAs: Potential biomarkers for cancer diagnosis prognosis and targets for therapy
    • DOI:10.1016/j.biocel.2009.12.014 Epub ahead of print
    • Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem Cell Biol. DOI:10.1016/j.biocel.2009. 12.014 (2009) (Epub ahead of print).
    • (2009) Int. J. Biochem Cell Biol.
    • Cho, W.C.1
  • 86
    • 35148886434 scopus 로고    scopus 로고
    • Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
    • Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163), 682-688 (2007).
    • (2007) Nature , vol.449 , Issue.7163 , pp. 682-688
    • Ma, L.1    Teruya-Feldstein, J.2    Weinberg, R.A.3
  • 87
    • 38049115129 scopus 로고    scopus 로고
    • Endogenous human microRNAs that suppress breast cancer metastasis
    • Tavazoie SF, Alarcón C, Oskarsson T et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451(7175), 147-152 (2008).
    • (2008) Nature , vol.451 , Issue.7175 , pp. 147-152
    • Tavazoie, S.F.1    Alarcón, C.2    Oskarsson, T.3
  • 89
    • 41849114566 scopus 로고    scopus 로고
    • MicroRNAs accurately identify cancer tissue origin
    • Rosenfeld N, Aharonov R, Meiri E et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol. 26(4), 462-469 (2008).
    • (2008) Nat. Biotechnol. , vol.26 , Issue.4 , pp. 462-469
    • Rosenfeld, N.1    Aharonov, R.2    Meiri, E.3
  • 90
    • 36048933639 scopus 로고    scopus 로고
    • Cancer of unknown primary origin: A decade of experience in a community-based hospital
    • Pimiento JM, Teso D, Malkan A, Dudrick SJ, Palesty JA. Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am. J. Surg. 194(6), 833-837 (2007).
    • (2007) Am. J. Surg. , vol.194 , Issue.6 , pp. 833-837
    • Pimiento, J.M.1    Teso, D.2    Malkan, A.3    Dudrick, S.J.4    Palesty, J.A.5
  • 91
    • 58049213696 scopus 로고    scopus 로고
    • Dicer, Drosha, and outcomes in patients with ovarian cancer
    • Merritt WM, Lin YG, Han LY et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359(25), 2641-2650 (2008).
    • (2008) N. Engl. J. Med. , vol.359 , Issue.25 , pp. 2641-2650
    • Merritt, W.M.1    Lin, Y.G.2    Han, L.Y.3
  • 92
    • 20144373433 scopus 로고    scopus 로고
    • Reduced expression of Dicer associated with poor prognosis in lung cancer patients
    • Karube Y, Tanaka H, Osada H et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 96(2), 111-115 (2005).
    • (2005) Cancer Sci. , vol.96 , Issue.2 , pp. 111-115
    • Karube, Y.1    Tanaka, H.2    Osada, H.3
  • 93
    • 22244467087 scopus 로고    scopus 로고
    • MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells
    • Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65(14), 6029-6033 (2005).
    • (2005) Cancer Res. , vol.65 , Issue.14 , pp. 6029-6033
    • Chan, J.A.1    Krichevsky, A.M.2    Kosik, K.S.3
  • 94
  • 95
    • 34548316982 scopus 로고    scopus 로고
    • MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells
    • Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4(9), 721-726 (2007).
    • (2007) Nat. Methods , vol.4 , Issue.9 , pp. 721-726
    • Ebert, M.S.1    Neilson, J.R.2    Sharp, P.A.3
  • 96
    • 66449136951 scopus 로고    scopus 로고
    • Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model
    • Kota J, Chivukula RR, O'Donnell KA et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6), 1005-1017 (2009).
    • (2009) Cell , vol.137 , Issue.6 , pp. 1005-1017
    • Kota, J.1    Chivukula, R.R.2    O'Donnell, K.A.3
  • 97
    • 73349094741 scopus 로고    scopus 로고
    • Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    • Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 27(35), 5924-5930 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.35 , pp. 5924-5930
    • Laurent-Puig, P.1    Cayre, A.2    Manceau, G.3
  • 98
    • 66749094784 scopus 로고    scopus 로고
    • Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2
    • 10-14 December, Abstract 708
    • Guix M, Aura CM, Jimenez J et al. Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2. San Antonio Breast Cancer Symposium San Antonio, TX, USA 10-14 December 2008 (Abstract 708).
    • (2008) San Antonio Breast Cancer Symposium San Antonio TX USA
    • Guix, M.1    Aura, C.M.2    Jimenez, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.